Showing results (2051-2060 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 3, 2013
Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2Patricia LoRusso, Karthik Venkatakrishnan, E Gabriela Chiorean, et al.
Investigational New Drugs|May 1, 1990
In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assayR Villa, N Zaffaroni, F Giuliani, et al.
Investigational New Drugs|May 1, 1990
Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group studyW P McGuire, J A Blessing, J S Berek, et al.
Investigational New Drugs|May 1, 1990
Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II studyW Scheithauer, H Samonigg, D Depisch, et al.
Investigational New Drugs|June 27, 2013
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trialS Y Moorcraft, I Chau, C Peckitt, et al.
Investigational New Drugs|January 31, 2013
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignanciesAung Naing, Roger Cohen, Grace K Dy, et al.
Investigational New Drugs|January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft modelsS Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Investigational New Drugs|January 10, 2013
Preclinical antitumor activity of a nanoparticulate SN38Mazin F Al-Kasspooles, Stephen K Williamson, David Henry, et al.
Investigational New Drugs|December 11, 2012
Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor modelYa-Jen Chang, Chin-Wei Hsu, Chih-Hsien Chang, et al.
Investigational New Drugs|December 18, 2012
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsMichael S Gordon, David S Mendelson, Mitchell Gross, et al.
Pageof 372